Labshake search

1 - 3 of 3 citations for "S1005" since 2019

• “The anti-angiogenic compound axitinib demonstrates low toxicity and anti-tumoral effects against medulloblastoma”

  Marina Pagnuzzi-Boncompagni, et al., bioRxiv - Cancer Biology 2020

  Quote: ... Cells were treated the next day with 5 µM axitinib (Selleck Chemicals S1005), a combination of etoposide (Selleck Chemicals S1225 ...

  Product cited:

  

  Axitinib

  Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of...

  Cat# S1005, SKU# S1005-100mg, 100mg, $120.00 Ask
• “The anti-angiogenic compound axitinib demonstrates low toxicity and anti-tumoral effects against medulloblastoma”

  Marina Pagnuzzi-Boncompagni, et al., bioRxiv - Cancer Biology 2020

  Quote: Cell viability of cultures treated for 48 hours with 5µM axitinib (Selleck Chemicals S1005), Cabozantinib (Selleck Chemicals S1119) ...

  Product cited:

  

  Axitinib

  Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of...

  Cat# S1005, SKU# S1005-100mg, 100mg, $120.00 Ask
• Cancer exosomes harbor diverse hypoxia-targeted mRNAs and contribute toward tumor angiogenesis

  Pan Zhang, et al., bioRxiv - Cancer Biology 2020

  Quote: ... or treated with both 50 µg/mL MDA-MB-231-HEXOs and 0.1 µM Axitinib (Selleck Chemicals, Cat No. S1005). After 24 h ...

  Product cited:

  

  Axitinib

  Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of...

  Cat# S1005, SKU# S1005-100mg, 100mg, $120.00 Ask